FDA approves Alzheimer's blood test that rivals spinal taps, brain scans

The FDA has approved C2N Diagnostics’ PrecivityAD2 blood test, providing a less invasive and accurate alternative to spinal taps and brain scans for identifying amyloid plaques associated with Alzheimer's disease.

This Wire brief sits within Fusion42's coverage of Digital Health.